Recently Added |View All
New CAR T Clinical Trials Underway at Roswell Park for Solid Tumor, Non-cancerous Diseases
While the focus and promise of CAR T-cell therapies has long been on liquid tumors and hematologic malignancies, new trials under way at Roswell Park Comprehensive Cancer Center are expanding the applications of immunotherapy to include other diseases.
Roswell Park Comprehensive Cancer Center is moving the science forward by offering clinical trials aimed at extending the benefits of those therapies to patients with all types of solid tumors.
Can NST-628 Fill the Treatment Void For Advanced Tumors with RAS or RAF Mutations?
A phase 1 clinical trial underway at Roswell Park Comprehensive Cancer Center will evaluate the potential of a “molecular glue” to treat MAPK pathway-mutated advanced solid tumors in patients who have exhausted standard treatment options.
Advances in Ovarian Cancer Treatment Show Promise for Longer Response, Survival Rates
While it remains the leading cause of death among patients with gynecologic cancers, new treatments are offering patients better outcomes and better quality of life.
Clinical Trial Utilizes Novel CAR Target for Relapsed/Refractory Multiple Myeloma
Most multiple myeloma patients with relapsed/refractory disease will undergo CAR T-cell therapy targeting B-cell maturation antigen (BCMA), a protein found on multiple myeloma cells.
Encouraging results from a phase 1 clinical trial conducted at Roswell Park Comprehensive Cancer Center between 2019-2020 have laid the foundation for a phase 1/2a study for patients with metastatic or unresectable triple negative breast cancer (mTNBC)
New Clinical Trials for Cervical Cancer Now Available at Roswell Park
Groundbreaking new treatments, including a handful of clinical trials, are now available for patients at Roswell Park Comprehensive Cancer Center, says gynecologic oncologist Karen McLean, MD, PhD, FCAOG.
Immunotherapies, Antibody Drug Conjugants Among Advances in Endometrial Cancer Treatment Options
While the majority of endometrial cancer cases are diagnosed early and patients have an excellent prognosis, those diagnosed with advanced or recurrent endometrial cancer often face a worse prognosis and their treatment can be more difficult.
Exclusive to Roswell Park, ‘Armored CAR’ Clinical Trial Targets CD19+ Hematologic Malignancies
A phase 1 clinical trial underway exclusively at Roswell Park Comprehensive Cancer Center will evaluate a novel chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed or refractory hematologic malignancies whose tumor ...
This site is intended for healthcare professionals